References

Risk of dementia in Parkinson’s disease: a community-based, prospective study

10.1212/wnl.56.6.730 · 2001 · External reference

Parkinson disease-associated cognitive impairment

10.1038/s41572-021-00280-3 · 2021 · External reference

IGF2 prevents dopaminergic neuronal loss and decreases intracellular alpha-synuclein accumulation in Parkinson’s disease models

10.1038/s41420-023-01734-1 · 2023 · External reference

An Alzheimer’s disease-derived biomarker signature identifies Parkinson’s disease patients with dementia

10.1371/journal.pone.0147319 · 2016 · External reference

Assessment of variability in the SOMAscan assay

10.1038/s41598-017-14755-5 · 2017 · External reference

Circulating insulin-like growth factor-1 and brain health: evidence from 369,711 participants in the UK biobank

10.1186/s13195-023-01288-5 · 2023 · External reference

Platelet-derived growth factor (PDGF)-BB protects dopaminergic neurons via activation of Akt/ERK/CREB pathways to upregulate tyrosine hydroxylase

10.1111/cns.13708 · 2021 · External reference

Predictors of cognitive impairment in newly diagnosed Parkinson’s disease with normal cognition at baseline: a 5-year cohort study

2023 · External reference

Global, regional, and national burden of disorders affecting the nervous system, 1990-2021: a systematic analysis for the global burden of disease study 2021

10.1016/s1474-4422(24)00038-3 · 2024 · External reference

Clinical diagnostic criteria for dementia associated with Parkinson’s disease

10.1002/mds.21507 · 2007 · External reference

Low-dose interleukin-2 in patients with mild to moderate Alzheimer’s disease: a randomized clinical trial

10.1186/s13195-025-01791-x · 2025 · External reference

Aptamer-based multiplexed proteomic technology for biomarker discovery

10.1371/journal.pone.0015004 · 2010 · External reference

Association of lipid levels with motor and cognitive function and decline in Parkinson’s disease

10.1111/psyg.13122 · 2024 · External reference

Machine learning-based prediction of cognitive outcomes in de novo Parkinson’s disease

10.1038/s41531-022-00409-5 · 2022 · External reference

IGF-1 gene therapy prevents spatial memory deficits and modulates dopaminergic neurodegeneration and inflammation in a parkinsonism model

10.1016/j.bbi.2024.05.013 · 2024 · External reference

Four questions to predict cognitive decline in de novo Parkinson’s disease

10.1038/s41531-025-00958-5 · 2025 · External reference

A proteogenomic view of Parkinson’s disease causality and heterogeneity

10.1038/s41531-023-00461-9 · 2023 · External reference

Serum uric acid as a putative biomarker in prodromal Parkinson’s disease: longitudinal data from the PPMI study

10.3233/jpd-230007 · 2023 · External reference

Neuroinflammation is linked to dementia risk in Parkinson’s disease

10.1093/brain/awad322 · 2024 · External reference

Do CSF biomarkers predict progression to cognitive impairment in Parkinson’s disease patients? A systematic review

10.1007/s11065-015-9307-8 · 2015 · External reference

Inflammatory CSF profiles and longitudinal development of cognitive decline in sporadic and GBA-associated PD

10.1038/s41531-023-00476-2 · 2023 · External reference

Insights into the role of platelet-derived growth factors: implications for Parkinson’s disease pathogenesis and treatment

2022 · External reference

IL-2 family cytokines: new insights into the complex roles of IL-2 as a broad regulator of T helper cell differentiation

10.1016/j.coi.2011.08.003 · 2011 · External reference

Diagnostic criteria for mild cognitive impairment in Parkinson’s disease: Movement Disorder Society task force guidelines

10.1002/mds.24893 · 2012 · External reference

Prediction of cognition in Parkinson’s disease with a clinical-genetic score: a longitudinal analysis of nine cohorts

10.1016/s1474-4422(17)30122-9 · 2017 · External reference

Unresolved reference

2017 · External reference

Relationship between circulating CD4+ T lymphocytes and cognitive impairment in patients with Parkinson’s disease

10.1016/j.bbi.2020.07.005 · 2020 · External reference

Immune cell metabolic dysfunction in Parkinson’s disease

10.1186/s13024-025-00827-y · 2025 · External reference

Insulin-like growth factor II prevents oxidative and neuronal damage in cellular and mice models of Parkinson’s disease

10.1016/j.redox.2021.102095 · 2021 · External reference

LRRK2 and GBA1 variant carriers have higher urinary bis(monacylglycerol) phosphate concentrations in PPMI cohorts

10.1038/s41531-023-00468-2 · 2023 · External reference

Plasma ceramide and glucosylceramide metabolism is altered in sporadic Parkinson’s disease and associated with cognitive impairment: a pilot study

10.1371/journal.pone.0073094 · 2013 · External reference

Longitudinal CSF biomarkers in patients with early Parkinson disease and healthy controls

10.1212/wnl.0000000000004609 · 2017 · External reference

Platelet-derived growth factor-BB has neurorestorative effects and modulates the pericyte response in a partial 6-hydroxydopamine lesion mouse model of Parkinson’s disease

10.1016/j.nbd.2016.06.002 · 2016 · External reference

Microvascular changes in Parkinson’s disease- focus on the neurovascular unit

10.3389/fnagi.2022.853372 · 2022 · External reference

Head-to-head comparison of aptamer- and antibody-based proteomic platforms in human cerebrospinal fluid samples from a real-world memory clinic cohort

10.3390/ijms26010286 · 2024 · External reference

Immunometabolism in brain aging and neurodegeneration: bridging metabolic pathways and immune responses

2024 · External reference

Signaling and function of Interleukin-2 in T lymphocytes

10.1146/annurev-immunol-042617-053352 · 2018 · External reference

Comprehensive proteomics of CSF, plasma, and urine identify DDC and other biomarkers of early Parkinson’s disease

10.1007/s00401-024-02706-0 · 2024 · External reference

Serum neurofilament light chain levels reflect cortical neurodegeneration in de novo Parkinson’s disease

10.1016/j.parkreldis.2020.04.009 · 2020 · External reference

Clinical variables and biomarkers in prediction of cognitive impairment in patients with newly diagnosed Parkinson’s disease: a cohort study

10.1016/s1474-4422(16)30328-3 · 2017 · External reference

Multimodal markers of immune activation predict cognitive outcomes in Parkinson’s disease

10.1016/j.bbi.2025.05.020 · 2025 · External reference

Cognitive function and quality of life in Parkinson’s disease: a cross-sectional study

10.3233/jpd-202097 · 2020 · External reference

High-throughput CSF proteomics and machine learning to identify proteomic signatures for Parkinson disease development and progression

10.1212/wnl.0000000000207725 · 2023 · External reference

Confidence intervals for a binomial proportion

10.1002/sim.4780120902 · 1993 · External reference

The economic impact of cognitive impairment in Parkinson’s disease

10.1002/mds.23661 · 2011 · External reference

Abnormalities of cerebral blood flow and the regional brain function in Parkinson’s disease: a systematic review and multimodal neuroimaging meta-analysis

10.3389/fneur.2023.1289934 · 2023 · External reference

The role of immune and inflammatory-related indicators in cognitive dysfunction and disease severity in patients with parkinson’s disease

10.1007/s00702-023-02704-8 · 2024 · External reference

Metascape provides a biologist-oriented resource for the analysis of systems-level datasets

10.1038/s41467-019-09234-6 · 2019 · External reference

Multimodal neuroimaging-based prediction of Parkinson’s disease with mild cognitive impairment using machine learning technique

10.1038/s41531-024-00828-6 · 2024 · External reference